Trevi Therapeutics, INC Form 4 insider transactions

Christopher Galletta, a key executive at Trevi Therapeutics, exercised stock options and acquired shares, increasing his holdings in the company.

James V. Cassella, Chief Development Officer of Trevi Therapeutics, Inc., was granted stock options for 400,000 shares on September 30, 2024.

Jennifer Good, CEO of Trevi Therapeutics, exercised stock options and sold shares of common stock on September 6 and September 9, 2024.

Trevi Therapeutics CEO Jennifer Good executed stock options and sold shares between September 3rd and September 5th, 2024.

Director David P. Meeker exercised stock options and sold shares of Trevi Therapeutics on August 27, 2024.

Thomas Sciascia, Chief Scientific Officer of Trevi Therapeutics, reports the acquisition and disposal of common stock and stock options on August 19, 2024.

Thomas Sciascia, Chief Scientific Officer of Trevi Therapeutics, exercised stock options and sold shares of common stock between August 14 and August 16, 2024.

Director Edward T. Mathers acquired 30,000 nonstatutory stock options in Trevi Therapeutics, Inc. on June 13, 2024.

Director James V. Cassella acquired 30,000 nonstatutory stock options in Trevi Therapeutics, Inc. on June 13, 2024.

Director Michael Heffernan acquired 30,000 nonstatutory stock options in Trevi Therapeutics, Inc. on June 13, 2024.

Director David P. Meeker acquired 30,000 nonstatutory stock options in Trevi Therapeutics, Inc. on June 13, 2024.

Dominick Colangelo, a director of Trevi Therapeutics, acquired 30,000 nonstatutory stock options on June 13, 2024.

Director Anne VanLent reports the acquisition of 30,000 nonstatutory stock options in Trevi Therapeutics, Inc.

Thomas Sciascia, Chief Scientific Officer of Trevi Therapeutics, exercised stock options and sold shares to cover the exercise cost and tax obligations on May 29, 2024.

Lisa Delfini, CFO of Trevi Therapeutics, reports the acquisition and disposal of common stock and stock options on May 22, 2024, including shares sold to cover tax obligations.

Trevi Therapeutics CEO Jennifer Good exercised stock options and sold shares on May 20, 2024, according to a Form 4 filing with the SEC.

Trevi Therapeutics CEO Jennifer Good reports the exercise of stock options and subsequent sale of shares on May 10, 2024.